Navigation Links
BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results
Date:3/17/2009

ember 31, 2008 2007 2008 2007 Revenues: Third parties $35,267 $9,159 $108,246 $31,003 Related parties 1,370 -- 6,621 -- Total Revenues 36,637 9,159 114,867 31,003 Cost of Goods Sold 17,437 7,676 57,557 26,716 Gross Margin 19,200 1,483 57,310 4,287 Sales and Marketing Expenses 13,415 1,953 39,666 4,377 General and Administration Expenses 4,012 4,933 13,898 10,780 Total Operating Expenses 17,427 6,886 53,564 15,157 Profit (Loss) From Operations 1,773 (5,403) 3,746 (10,870) Other Income (Expense): Interest Income 2 179 70 620 Interest (Expense) (1,531) (957) (6,301) (1,047) Debt Issuance Cost Amortization (210) (140) (840) (140) Equity Method Investment Gain (321) (264) 675 (264) Other Income -- 10 -- 81 Total Other Income (Expense) (2,060) (1,172) (6,396) (750) Loss Before Provision For Income Taxes (287) (6,575) (2,650) (11,620) Provision For Income Taxes (1,406) 15 792 15 Net Loss $1,119 $(6,590) $(3,442) $(11,635) Basic and Fully-Diluted Loss Per Share $0.03 $(0.21) $(0.09) $(0.41) Basic and Fully-Diluted Weighted-average Shares Outstanding 40,185 30,708 38,617 28,120 BMP Sunstone Corporation and Subsidiaries Condensed Consolidated Balance Sheets
'/>"/>
SOURCE BMP Sunstone Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. BMP Sunstone to Present at UBS Global Healthcare Services Conference
2. BMP Sunstone Adopts Voluntary Executive Compensation Restrictions in 2008 and 2009
3. BMP Sunstone Receives High Tech Status
4. BMP Sunstone to Present at the 20th Annual Piper Jaffray Health Care Conference
5. BMP Sunstone Acquires Runchang Capsule and Related LFHC Technology
6. BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesdays Call
7. BMP Sunstone Reports Third Quarter 2008 Financial Results
8. BMP Sunstone Announces Participation in November Investor Conferences
9. BMP Sunstone Announces Participation in September Investor Conference
10. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
11. BMP Sunstone Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... THOUSAND OAKS, Calif., Dec. 14 Array ... Inc.(Nasdaq: AMGN ) today announced that they ... rights to Array,s small-molecule glucokinase activator program, including ... clinical trial in patients with Type 2 diabetes. ... agreement, Array will receive an upfront payment of ...
(Date:12/14/2009)... The third edition of ... published by the Infusion Nurses Society (INS), ... extravasation.(1) Anthracyclines are a group of chemotherapy ... have been used in the treatment of various ... ,, According to the INS publication: "In ...
(Date:12/14/2009)... WALTHAM, Mass., Dec. 14 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that, ... the atrial fibrillation drug market will increase more ... $6.1 billion in 2018 in the United States, ... Japan. ,, The new Pharmacor report entitled ...
(Date:12/11/2009)... 11 Dendreon Corporation (Nasdaq: DNDN ... previously announced public offering have exercised in full ... of common stock at the public offering price ... the option increases the size of the offering ... stock. Dendreon expects to receive net proceeds ...
Breaking Biology Technology:Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3
... Million in 3Q08 -- ... $16.5 Million -- -- ... NEW YORK, Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, Inc. ... through the development, manufacture and commercialization,of a broad range of ...
... AVIV, Israel, November 10 InspireMD, developers of,the ... MGuard(TM),was successfully implanted in a complex lesion in ... was performed by Dr. Dariusz Dudek and was ... New Approach to Treating Thrombus Containing Lesions (ACS, ...
... ... ... pharmaceuticals company, today announced,that it had successfully closed a third ... developing its unique,CriticalMix delivery technology and matching pipeline of candidate ...
Other Biology Technology:American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 2American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 3American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 4American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 5American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 6American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 7American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 8MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 2MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 3MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 4Critical Pharmaceuticals Raise GBP650K 2Critical Pharmaceuticals Raise GBP650K 3
(Date:12/14/2009)... HOUSTON -- (Dec. 14, 2009) -- Researchers at Rice ... a single nanoparticle that can be tracked in real ... cells, tags them with a fluorescent dye and kills ... the first examples from a growing field called "theranostics" ... treat diseases in a single procedure. , The research ...
(Date:12/14/2009)... as a clean-burning, renewable fuel that could help wean ... caused by ozone, compared with gasoline, especially in winter, ... , Ozone production from both gasoline and E85, ... percent ethanol, is greater in warm sunny weather than ... because heat and sunlight contribute to ozone formation. But ...
(Date:12/14/2009)... Engineering Society (BMES) have founded a new journal ... CVET is a forum for research on ... The first issue of the new quarterly journal will ... publications at Springer, Annals of Biomedical Engineering ... Cardiovascular Engineering and Technology will present a wide ...
Breaking Biology News(10 mins):Tracking new cancer-killing particles with MRI 2Ethanol-powered vehicles generate more ozone than gas-powered ones 2Ethanol-powered vehicles generate more ozone than gas-powered ones 3Biomedical Engineering Society's new journal to be published by Springer 2Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 1Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 2Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 3Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 4Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 5Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 1Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 2Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 3Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 4Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 5Vein Condition May Mask Serious Clot Disorder 52152 1Vein Condition May Mask Serious Clot Disorder 52152 2
... plants, human antibodies that could be used to treat ... 2005 American Society for Microbiology Biodefense Research Meeting. , ... is likely to strike at a time and place ... unpredictable nature of such events compels us to develop ...
... before they reach hospital, has the potential to save many ... over a million children die of malaria in Africa. The ... For those who do make it to hospital, half of ... given by injection, is not possible to administer outside hospital, ...
... of breast cancer,patients have an abnormality in a ... along that pathway may be,especially effective for treating ... Texas M. D. Anderson Cancer Center.", , A ... the phosphatidylinositol 3 kinase (PI3K),pathway to breast cancer ...
Other Biology News:Antibodies from plants protect against anthrax 2